美国媒体发现除了稀土外，我国手中还有多张牌可打

Group 1 - China has quietly tightened the approval process for rare earth exports, leading to production halts in multiple automotive production lines in Europe and signaling distress from the U.S. pharmaceutical industry [1][5] - China controls over 92% of the global refined rare earth production, and 80% of the raw materials for amoxicillin sold in the U.S. come from China, indicating a significant dependency on Chinese exports [1][5] - The tightening of rare earth export approvals has created waves in the high-tech manufacturing sector in Europe and the U.S., as rare earths are essential for national development and technological advancement [3][4] Group 2 - The U.S. pharmaceutical supply chain is heavily reliant on China, with experts warning that any restrictions from China could lead to a critical shortage of medications in the U.S. [5][8] - Historical context shows that the U.S. has been aware of its dependency on Chinese imports, with previous administrations attempting to investigate and address the vulnerabilities in the pharmaceutical sector [7][8] - Rebuilding the U.S. pharmaceutical supply chain is projected to take at least five years, highlighting the complexity and time required to establish domestic production capabilities [7][8] Group 3 - The U.S. is also aware of China's leverage in other critical sectors, including rare metals, photovoltaic components, batteries, and new materials, which could further impact the U.S. economy if restrictions are imposed [10] - As China's overall strength continues to grow, it is recognized as a key player in the global supply chain, with potential disruptions having far-reaching consequences for the international market [10]